vTv Therapeutics (NASDAQ:VTVT) Shares Cross Below Fifty Day Moving Average – Here’s Why

vTv Therapeutics Inc. (NASDAQ:VTVT) passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $33.89 and traded as low as $30.71. vTv Therapeutics shares last traded at $31.66, with a volume of 156,641 shares trading hands.

Wall Street Analyst Weigh In

VTVT has been the subject of several recent research reports. Zacks Research downgraded vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. Weiss Ratings raised vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Monday, May 18th. Wall Street Zen raised shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Rodman & Renshaw started coverage on vTv Therapeutics in a research report on Tuesday, June 30th. They set a “buy” rating and a $67.00 price objective for the company. Finally, BTIG Research lifted their target price on shares of vTv Therapeutics from $49.00 to $57.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, vTv Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $56.67.

vTv Therapeutics Stock Down 0.0%

The company has a market cap of $124.74 million, a PE ratio of -34.04 and a beta of 0.25. The business’s fifty day moving average is $33.89 and its 200-day moving average is $35.26.

vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 earnings per share for the quarter, beating the consensus estimate of $0.21 by $1.44. The company had revenue of $36.84 million for the quarter, compared to analysts’ expectations of $20.00 million. Analysts forecast that vTv Therapeutics Inc. will post -2.19 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in VTVT. Goldman Sachs Group Inc. purchased a new stake in vTv Therapeutics in the 4th quarter worth approximately $221,000. 683 Capital Management LLC bought a new stake in vTv Therapeutics during the 4th quarter worth approximately $731,000. Finally, Geode Capital Management LLC lifted its holdings in vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after purchasing an additional 12,896 shares in the last quarter. 17.51% of the stock is currently owned by institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.